Sagimet Biosciences Inc.
Income Statement
| Line Item | FY2023 |
|---|---|
| Revenue | $2.0M |
| Cost of Revenue | — |
| Gross Profit | — |
| Gross Margin | — |
| Operating Expenses | |
| Research & Development | $19.8M |
| SG&A Expense | $13.0M |
| Operating Income | $-30.7M |
| Operating Margin | -1,537.0% |
| Interest Expense | — |
| Pretax Income | — |
| Income Tax Expense | — |
| Net Income | $-27.9M |
| Net Margin | -1,393.8% |
| EPS (Basic) | $-0.89 |
| EPS (Diluted) | $-0.89 |
| Shares Outstanding (Basic) | 31.4M |
| Shares Outstanding (Diluted) | 31.4M |
| Dividends Per Share | — |